TOL 101
Alternative Names: TOL-101Latest Information Update: 23 Sep 2015
At a glance
- Originator The Cleveland Clinic Foundation
- Developer Tolera Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 23 Sep 2015 No recent reports on development identified - Phase-I/II for Transplant rejection (Prevention) in USA (IV)
- 23 Sep 2015 No recent reports on development identified - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
- 16 Oct 2012 TOL 101 is still in phase I/II trials for Transplant rejection (prevention) in US